Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | YWHAG | P61981 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336413 | 0.98 | ALDH1A1 (0.59) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL25194643 | 0.98 | ALDH1A1 (0.59) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL1929368 | 0.98 | ALDH1A1 (0.59) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL5563187 | 0.86 | MAPT (0.54) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL10157709 | 0.85 | MAPT (0.47) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL5252902 | 0.85 | MAPT (0.52) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL1929073 | 0.85 | MAPT (0.61) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL29039626 | 0.85 | MAPT (0.52) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL31210319 | 0.85 | MAPT (0.61) | ALDH1A1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL29959068 | 0.85 | MAPT (0.59) | ALDH1A1POLBMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| EP-2190834-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | claimed |
| EP-2065380-A1 | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-03 | — | — | EP | claimed |
| WO-2009024332-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | claimed |
| CN-119431239-A | Compounds, pharmaceutical compositions, kits and uses thereof | 密执安大学评议会 | 2025-02-14 | — | — | CN | disclosed |
| CN-113710241-B | Substituted bicyclic and tetracyclic quinones and related methods of use | 密执安大学评议会 | 2024-11-15 | — | — | CN | disclosed |
| EP-4427812-A2 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents of the University of Michigan (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3934634-B1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | UNIV MICHIGAN REGENTS (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220162167-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND USE THEREOF AS ANTI-CANCER AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-26 | — | — | US | disclosed |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | NEUROPORE THERAPIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2003000256-A9 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | ALDH1A1 4634/4885POLB 2606/4885MAPT 100/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | ALDH1A1 3632/4885POLB 2588/4885MAPT 899/4885 |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | F2, F11, SERPINC1 | ALDH1A1 96/4885POLB 1309/4885MAPT 4763/4885 |
| US-20220162167-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND USE THEREOF AS ANTI-CANCER AGENTS | MCL1, NQO1, GLS | ALDH1A1 910/4885POLB 728/4885MAPT 2167/4885 |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | TLR3, TLR6, TLR4 | ALDH1A1 4515/4885POLB 2819/4885MAPT 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.